title: Proliferative activity of colonic mucosa at different distances from primary adenocarcinoma as determined by the presence of statin: a nonproliferation-specific nuclear protein.
abstract: The field change is one hypothesis concerning the development of colorectal carcinoma. Removal of a carcinoma without its entire surrounding altered mucosa may result in the development of a recurrence. S44, a monoclonal antibody directed against statin, a nuclear protein expressed in nonproliferating cells in either a quiescent or senescent state, was used to determine the rate of cell growth in colorectal mucosa at different distances from carcinomas. The specimens of 18 patients undergoing resection of a colorectal carcinoma were immediately opened after operation, and strips of mucosa were taken at distances of 1 cm, 5 cm, and 10 cm from the carcinoma. For each location, 10 longitudinally oriented crypts were evaluated for statin-positive cells identified by the presence of a dark brown peroxidase-conjugated antibody reaction product. The average percentage of statin-positive cells per crypt was significantly lower at a 1-cm distance from the carcinoma compared with the mucosa located 5 and 10 cm from the carcinoma (20.89 +/- 4.33 at 1 cm, 32.41 +/- 5.27 at 5 cm, and 34.23 +/- 6.45 at 10 cm). None of the calculated parameters showed any significant difference between the 5-cm and 10-cm locations. The fact that the proliferation rate of the mucosal cells returns to the normal level at 5 cm from the margin of the carcinoma suggests that cells located within this distance still retain proliferative potential even though they are morphologically indistinguishable from their normal counterparts. We conclude that failure to remove this transitional, potentially proliferative mucosa may result in subsequent development of anastomotic or perianastomotic recurrences.
authors.affiliation: Department of Surgery, Sir Mortimer B. Davis-Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Kyzer
authors.forename: B
authors.initials: B
authors.lastname: Mitmaker
authors.forename: P H
authors.initials: PH
authors.lastname: Gordon
authors.forename: H
authors.initials: H
authors.lastname: Schipper
authors.forename: E
authors.initials: E
authors.lastname: Wang
mesh_terms: D000911:Antibodies, Monoclonal; D018797:Cell Cycle Proteins; D002455:Cell Division; D002467:Cell Nucleus / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D003106:Colon / Q000378:metabolism / Q000473:pathology*; D015179:Colorectal Neoplasms / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D007413:Intestinal Mucosa / Q000378:metabolism / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D020648:Peptide Elongation Factor 1; D011506:Proteins / Q000032:analysis*; D012007:Rectum / Q000378:metabolism / Q000473:pathology*
chemical_list: D000911:Antibodies, Monoclonal; D018797:Cell Cycle Proteins; C503234:EEF1A2 protein, human; D020648:Peptide Elongation Factor 1; D011506:Proteins